CONCLUSIONS	For patients with chronic hepatitis C genotype 2/3 infection , 24weeks of peginterferon alfa-2b ( 1.5 g/kg/wk ) plus weight-based ribavirin remains a standard-of-care therapy ; however , treatment for 16weeks may be considered for patients with undetectable HCV RNA at week 4 of the treatment .\